New Zealand Gazette – 1997 – No. 161

Page 3780

✨ Health Notices



3780
NEW ZEALAND GAZETTE
No. 161

Health

Health Reforms (Transitional Provisions) Act 1993

Appointment of Directors of Residual Health Management Unit

Pursuant to section 18 (2) of the Health Reforms (Transitional Provisions) Act 1993, and clause 2 (1) and 3 of the Second Schedule to the Health and Disability Services Act 1993, I appoint the persons named in the Schedule to this notice to the positions on the board of the Residual Health Management Unit identified, and for the term and on the condition appearing in that Schedule.

Schedule

Name Position Term
Ian Miller Chairperson 2 November 1997 to 30 June 1998
Peter Kemp Director 1 November 1997 to 30 June 1998

Condition

Compliance with the Management Agreement dated 30 September 1993 between the Minister of Health and the Residual Health Management Unit.

Dated at Wellington this 30th day of October 1997.

HON. BILL ENGLISH, Minister of Health.

go8192

Medicines Act 1981

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Rivastigmine hydrogen tartrate 0.8 mg, 1.6 mg, 2.4 mg, 4.8 mg, 7.2 mg and 9.6 mg equivalent to 0.5 mg, 1 mg, 1.5 mg, 3 mg, 4.5 mg and 6 mg rivastigmine base Capsules Novartis Pharma AG., Basle, Switzerland Exelon

Note: This consent is valid for 2 years from the date of publication of this notice.

Dated this 4th day of November 1997.

G. R. BOYD, Chief Adviser, Regulation and Safety, pursuant to delegation given by the Minister of Health on 20 February 1997.

go7997

Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Ibuprofen 200 mg Tablet Wyeth SpA., Aprilia (LT), Italy Act-3
Ibuprofen 200 mg Tablet, capsule shaped Wyeth SpA., Aprilia (LT), Italy Act-3
Sumatriptan succinate 140 mg equivalent to 100 mg sumatriptan base Tablet Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Imigran 100
Sumatriptan succinate 70 mg equivalent to 50 mg sumatriptan base Tablet Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Imigran 50
Ranitidine bismuth citrate 400 mg Tablet, film coated Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Pylorid
Abciximab 2 mg/mL in 5 mL, 20 mL Injection, vial Centocor BV., Leiden, The Netherlands ReoPro
Oestradiol 25 mg Implant Organon (Ireland) Limited, Swords, Co Dublin, Eire Riselle


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa — PDF NZ Gazette 1997, No 161


NZLII — PDF NZ Gazette 1997, No 161




✨ LLM interpretation of page content

🏥 Appointment of Directors of Residual Health Management Unit

🏥 Health & Social Welfare
30 October 1997
Appointments, Residual Health Management Unit, Directors
  • Ian Miller, Appointed Chairperson
  • Peter Kemp, Appointed Director

  • HON. BILL ENGLISH, Minister of Health

🏥 Provisional Consent to the Distribution of a New Medicine

🏥 Health & Social Welfare
4 November 1997
Medicines, Provisional Consent, Rivastigmine hydrogen tartrate, Exelon
  • G. R. BOYD, Chief Adviser, Regulation and Safety

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
Medicines, Consent, Ibuprofen, Sumatriptan succinate, Ranitidine bismuth citrate, Abciximab, Oestradiol